NCT06596473

A Study of BG-C477 in Participants With Advanced Solid Tumors

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 310 (estimated)
• Sponsor: BeOne Medicines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.

Detailed description

This new study will check how safe and helpful a potential anticancer drug called BG-C477 is. This drug will be tested by itself or combined with other anticancer agents. The purpose of this study is to test if BG-C477 is safe and if it works in people with your disease when it is given on its own and in combination with other anticancer agents. Note: Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	BG-C477	Administered intravenously.
DRUG	Tislelizumab	Administered intravenously.
DRUG	Chemotherapy	Administered in accordance with relevant local guidelines and/or prescribing information.

Timeline

• Start date: 2024-10-03
• Primary completion: 2027-12-31
• Completion: 2027-12-31
• First posted: 2024-09-19
• Last updated: 2026-04-15

Locations

25 sites across 4 countries: United States, Australia, China, New Zealand

Regulatory

• FDA-regulated drug study